Sutro Biopharma (STRO) Common Equity (2016 - 2026)

Sutro Biopharma has reported Common Equity for 10 years, with the latest figure at -$132.5 million in Q4 2025.

• Quarterly Common Equity fell 396.97% year-over-year to -$132.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$132.5 million (down 396.97% YoY) and the FY2025 annual result came in at -$132.5 million, down 396.97% from the prior year.
• Common Equity eased to -$132.5 million in Q4 2025 per STRO's latest filing, from -$87.3 million in the prior quarter.
• Over five years, Common Equity peaked at $307.5 million in Q2 2021 and troughed at -$132.5 million in Q4 2025.
• A 5-year average of $137.9 million and a median of $153.4 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2021 and 2025: Common Equity surged 274.41% in 2021, then slumped 396.97% in 2025.
• Over 5 years, Common Equity stood at $252.6 million in 2021, then retreated by 14.06% to $217.0 million in 2022, then tumbled by 31.05% to $149.6 million in 2023, then slumped by 70.2% to $44.6 million in 2024, then tumbled by 396.97% to -$132.5 million in 2025.
• According to Business Quant data, Common Equity over the past three periods registered -$132.5 million, -$87.3 million, and -$32.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.